Home › Research › Brain scans and imaging
Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease
Marina Scop Madeiros, Pâmela C.L. Ferreira, Bruna Bellaver, Emma Patrice Ruppert, Hussein Zalzale, Carolina Soares, Guilherme Bauer‐Negrini, Guilherme Povala et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Clinical stages showed a progressively increased prevalence of Aβ-positivity and higher entorhinal tau PET pathology from cognitively normal (CN) to SOCD, MCI, and dementia in both tracers. MBI and SCD transitional groups showed no increased Aβ or tau pathology compared to CN (Figure 2). For this reason, only SOCD was considered part of stage 2 for following analyses. All tested biological staging strategies showed moderate agreement (0.34-0.59) with clinical stages using either tracers. The distribution of biological across clinical stages were similar for FTP and MK, with MK-6240 showing lower PPV values in earlier stages than FTP (Table 1). Our results support that AA-2024 biological and clinical stages show similar clinical-biological concordance using either Flortaucipir or MK-6240, although this can vary based on methods tested in the study. The MBI and SCD clinical subgroups showed no difference of pathological burden to clinical stage 1, while SOCD transitional stage showed higher burden compared to stage 1.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 446 participants. This study compared two tau PET tracers for staging Alzheimer's disease and found moderate agreement between biological and clinical staging with either tracer. It is a diagnostic comparison study and does not test any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Madeiros, M. S., Ferreira, P. C., Bellaver, B., Ruppert, E. P., Zalzale, H., Soares, C., et al. (2025). Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70857_107236
Vancouver
Madeiros MS, Ferreira PC, Bellaver B, Ruppert EP, Zalzale H, Soares C, et al. Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70857_107236. PMID: 41452137.
BibTeX
@article{madeiros2025-41452137,
author = {Madeiros, Marina Scop and Ferreira, Pâmela C.L. and Bellaver, Bruna and Ruppert, Emma Patrice and Zalzale, Hussein and Soares, Carolina and Bauer‐Negrini, Guilherme and Povala, Guilherme and others},
title = {{Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70857_107236},
pmid = {41452137},
url = {https://doi.org/10.1002/alz70857_107236}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Clinical stages showed a progressively increased prevalence of Aβ-positivity and higher entorhinal tau PET pathology from cognitively normal (CN) to SOCD, MCI, and dementia in both tracers.
- MBI and SCD transitional groups showed no increased Aβ or tau pathology compared to CN (Figure 2).
- For this reason, only SOCD was considered part of stage 2 for following analyses.
- All tested biological staging strategies showed moderate agreement (0.34-0.59) with clinical stages using either tracers.
- The distribution of biological across clinical stages were similar for FTP and MK, with MK-6240 showing lower PPV values in earlier stages than FTP (Table 1).
Why it matters
This study compared two tau PET tracers for staging Alzheimer's disease and found moderate agreement between biological and clinical staging with either tracer. It is a diagnostic comparison study and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Study designlongitudinal study
- Participants446
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 446 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Tharick Ali Pascoal: h-index 61 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41452137) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70857_107236
- PubMed: 41452137
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.